Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Vancomycin alone Clear all
Recruiting Early Phase 1 Interventional

Fecal Microbiota Transplant for Patients With Chronic Pouchitis

NCT05829109
View directory record Official record
Conditions
Chronic Pouchitis, Pouchitis
Interventions
Fecal Microbiota Transplant (FMT)
Drug
Lead sponsor
Maia Kayal
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

NCT01401023
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile
Interventions
Tigecycline
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
East Lansing, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 6, 2026, 6:44 PM EDT
Terminated Phase 2 Interventional Results available

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

NCT03617445
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 6, 2026, 6:44 PM EDT
Recruiting Phase 2 Interventional

Further MT for Antibiotic-Resistant Bacterial Colonization

NCT05835206
View directory record Official record
Conditions
Intestinal Multi-drug Resistant Organism Colonization
Interventions
Microbiome Therapeutic, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 6, 2026, 6:44 PM EDT
Completed No phase listed Observational

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

NCT04317963
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Bezlotoxumab, Standard CDI treatment
Biological · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 3 Interventional Results available

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 6, 2026, 6:44 PM EDT
Withdrawn Not applicable Interventional

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

NCT03046901
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Interventions
Vancomycin
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 6:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant for Primary CDI

NCT03795233
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
Biological · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

NCT03476317
View directory record Official record
Conditions
Crohn Disease
Interventions
Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Fluconazole
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 6, 2026, 6:44 PM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 4 Interventional

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

NCT03880539
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
bezlotoxumab, Vancomycin Oral
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization

NCT03063437
View directory record Official record
Conditions
Antibiotic Resistant Strain
Interventions
Encapsulated fecal microbiota preparation, Encapsulated placebo
Biological
Lead sponsor
Microbiome Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

NCT02135302
View directory record Official record
Conditions
Impaired Hepatic Function
Interventions
eravacycline
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Lakewood, Colorado • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 6, 2026, 6:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Study of VE303 in Healthy Adult Volunteers

NCT04236778
View directory record Official record
Conditions
Healthy Volunteers
Interventions
VE303, Oral Vancomycin
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 6, 2026, 6:44 PM EDT
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 6, 2026, 6:44 PM EDT